Next week, IRBM’s Vice Presidents, Dan Conlon and Michele Luche will be attending the annual JP Morgan Healthcare Conference – the largest healthcare investment symposium in the industry. Get in touch to organise a meeting with Dan and Michele to…
We were delighted to author a recent Bioanalysis Zone article discussing the power of high-resolution mass spectrometry (HRMS) when investigating peptide-based modalities in drug discovery. In the article, Simone Esposito, Research Investigator in the DMPK group, explores the extensive applications of the technology for…
Our Global VP of Sales and Marketing, Heidi Kingdon Jones, is attending TIDES Europe: Oligonucleotide and Peptide Therapeutics in Amsterdam. Running from November 12-15, the event is Europe's primary forum for thought leaders in this growing field to network and…
From November 11-13, we will be attending BIO-Europe in Hamburg. Our Global VP of Sales and Marketing, Heidi Kingdon Jones, and VP of North American Business Development, Michele Luche, will be on hand to talk about our exceptional drug discovery…
From October 24-25, our Vice President of North American Business Development, Dan Conlon, is attending the Peptide Therapeutics Symposium at the Salk Institute in California. Now in its 14th year, the event unites key opinion leaders and eminent researchers in…
Our Chief Scientific Officer, Carlo Toniatti, has been featured in The Medicine Maker, where he explored how we can catalyse the discovery and development of oncology drugs. In the article, he discusses how to overcome the challenges in developing efficacious…
Our Director of Peptide Chemistry, Elisabetta Bianchi, will be attending and speaking at the 1st International Oligonucleotide and Peptides Conference (IOPC 2019) in Milan from September 17-18. The event will cover important and trending topics at the forefront of oligonucleotide…
Next week our Global Vice President of Sales and Marketing, Heidi Kingdon Jones, and Vice President of North American Business Development, Daniel Conlon, will be attending Discovery on Target in Boston. The conference brings the biopharma industry together to share…
9th September 2019, Pomezia, Italy - IRBM today announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies against a novel…
Our Vice President of North American Business Development, Daniel Conlon, will be at the Boston BD conference on September 10. This invitation-only event brings together Biopharma thought leaders to network and explore insights into the business challenges and opportunities facing…